Disappointing retail earnings and concerns about bloated valuations are weighing down on retail sentiment toward some stocks.
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.
After the best week of 2024 on excitement over President-elect Trump’s policies, Wall Street lost momentum last week on sticky inflation and the Fed’s hawkish comments. The S&P 500 dropped more than...
Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...
Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.
Altimmune is betting big on its investigational metabolic diseases candidate pemvidutide.
Novavax CEO John Jacobs said the biopharma is looking to expand beyond COVID-19 and influenza.
The new hire’s background includes CFO roles at several biotech firms acquired in high-profile deals, such as Sirna Therapeutics (acquired by Merck) and ILEX Oncology (acquired by Genzyme).